For China cancer drug developer, Bristol-Celgene deal poses big ripple effects

Celgene is famous for cultivating a constellation of biotech partners — companies whose fortunes are poised to be shifted by last month’s news that Bristol-Myers Squibb plans to buy Celgene in a $74 billion deal.

One of those partners is BeiGene, among the buzziest companies in China’s rising biotech sector and one that could feel ripple effects.

https://www.statnews.com/2019/02/13/for-a-chinese-cancer-drug-developer-bristol-celgene-deal-is-poised-to-have-big-ripple-effects/